Janux Therapeutics Inc Asset Resilience Ratio
Janux Therapeutics Inc asset resilience ratio. Janux Therapeutics Inc (JANX) has an Asset Resilience Ratio of 87.97% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See JANX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Janux Therapeutics Inc (2020–2025)
Asset resilience ratio of Janux Therapeutics Inc from 2020 to 2025. This chart shows how Janux Therapeutics Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Janux Therapeutics Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Janux Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Janux Therapeutics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $904.56 Million | 87.97% |
| Total Liquid Assets | $904.56 Million | 87.97% |
Asset Resilience Insights
- Very High Liquidity: Janux Therapeutics Inc maintains exceptional liquid asset reserves at 87.97% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Janux Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Janux Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 36.07% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
Janux Therapeutics Inc Asset Resilience Ratio by Year (2020–2025)
Janux Therapeutics Inc asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Janux Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 90.74% | $914.23 Million | $1.01 Billion | +34.73pp |
| 2024-12-31 | 56.01% | $594.57 Million | $1.06 Billion | -29.38pp |
| 2023-12-31 | 85.39% | $324.82 Million | $380.41 Million | +9.68pp |
| 2022-12-31 | 75.71% | $275.59 Million | $364.01 Million | -13.64pp |
| 2021-12-31 | 89.35% | $339.38 Million | $379.82 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $16.22 Million | -- |
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in… Read more